Introduction
============

The RHO GTPase enzyme family, including RHOA, Rac, and cdc42, is essential for diverse biological processes, including cell morphology phenotypes, cell polarity, and cell migration, in diverse cancer types ([@B13]; [@B23]; [@B43]; [@B20]; [@B67]). Recently, it was shown that RHOA can be targeted by small molecule inhibitors, in cancer, implicating it as a potential druggable target ([@B60]; [@B5]). Due to a scarcity of RHOA reviews in the field of gastric cancer (GC), our focus herein is limited to RHOA, and its related GTPase family members ([@B13]; [@B25]; [@B23]; [@B20]; [@B67]) in GC.

Structural domains of RHO GTPase family members include a downstream effector protein-binding, and a GTP-/GDP-binding, domain ([@B23]). RHOA, like other RHO GTPases, is regulated by guanine nucleotide-exchange factors (GEFs), GTPase-activating proteins (GAPs), and guanine nucleotide-dissociation inhibitors (GDIs) ([@B23]). RHOA activation, by GEFs, facilitates its binding to GTP, as well as its release of GDP ([@B25]). Activated RHOA then recruits downstream effector proteins, including ROCK, LIMK, MLC, cofilin, PKN1, MYPT-1, and mammalian homolog of diaphanous (mDia) ([@B59]; [@B23]; [@B57]), and it is involved in actin reorganization, cell motility, and cell migration ([@B23]; [@B57]) ([Figure 1](#F1){ref-type="fig"}). As opposed to GEFs, GAPs inactivate various RHO-GTPase forms (e.g., RHOA-GDP) ([@B23]). Finally, GDIs interact with RHOA-GDP complexes to sequester RHOA from membranes, thus suppressing their activation ([@B11]; [@B37]).

![RHOA schematic structure and its downstream signaling. **(A)** Schematic structure of RHOA and a GEF protein, LARG (ARHGEF12), were represented (RCSB PDB ID: 1X86). **(B)** RHOA downstream signaling was represented, regarding actin reorganization, cell motility, and cell migration.](fgene-10-00438-g001){#F1}

Recently, roles for RHOA in cell motility have been identified, in many diverse types of cancer ([@B57]), but RHOA's clinical significance (including therapeutic feasibility), to GC, one of the most lethal cancers in East Asia ([@B30]), remains little known. Herein, the functional roles of RHOA, and its clinical relevance to GC, are systematically reviewed throughout the literature. Specifically, we find that RHOA is a strong potential druggable target, as well as a biomarker candidate, for GC, which currently lacks effective targeted therapies.

RHOA Functions and Its Biological Behavior in GC
================================================

RHOA Functions in Second-Generation Cancer Hallmarks
----------------------------------------------------

First, we explored literature regarding RHOA, in gastric cancer, in PubMed, using the search terms, "RHOA," "expression," and "cancer," as of March 6, 2018, resulting in 1,536 articles. Subsequently, we manually inspected the presence of term "gastric" in the article titles to secure RHOA's relevance to GC, resulting in 63 publications. Then, we co-searched the term "RHOA" with the terms in the ten 2nd-generation hallmark phrases ([@B22]) in abstracts and main texts of the 63 publications. We extracted 47 most relevant articles, regarding hallmarks of the cancer. These 47 were the basis for this section ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). Along with the 47, manually selected publications were also reviewed in this section.

Recently, a second generation of cancer hallmarks was proposed ([@B22]), including: (1) activation of invasion and metastasis; (2) resistance to cell death; (3) sustainment of proliferative signaling; (4) evasion of growth suppressors; (5) dysregulation of cellular energetics; (6) replicative immortality; (7) angiogenesis; (8) genome instability and mutation; (9) tumor-promoting inflammation; and (10) avoidance of immune destruction. Using these, we assigned RHOA functions, from the 47 identified publications, according to relevance to the 10 cancer hallmarks. These 47 were then aligned to the three hallmark terms: activation of invasion and metastasis (term \#1, above); resistance to cell death (term \#2); and sustainment of proliferative signaling (term \#3) ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). The other cancer hallmark terms were not revealed in these 47 publications, but we strongly believe that RHOA signaling associates with all 10.

As shown in [Supplementary Figure S2](#SM1){ref-type="supplementary-material"}, most of the publications were assigned to term \#1, "activation of invasion and metastasis." In GC, this hallmark term associates with RHOA, in signal pathways ([@B10]; [@B50]; [@B2]; [@B78]; [@B18]). During GC cancer cell migration, a sialylated glycan antigen, Sialyl-Lewis X (SLe^x^, synthesized by ST3GAL4), is often expressed on cell surfaces ([@B18]). Through ST3GAL4 expression, leading to SLe^x^ biosynthesis, activation of RHOA, as well as c-Met, associates with SLe^x^-induced GC invasion phenotypes ([@B18]). In recent studies ([@B50]; [@B2]), lysophosphatidic acid (LPA), through Neuroepithelial Cell Transforming 1 (NET1, a protein upregulated in GC tissues) ([@B42]), activates RHOA, leading to cell invasion and migration. We especially noted that *NET1* mRNA expression was upregulated in gastric epithelia infected by *Helicobacter pylori* (*H. pylori*), the primary risk factor for gastric carcinogenesis ([@B10]).

One proposed mechanism of tumorigenesis, via *H. pylori* infection of gastric epithelial cells, with regard to cell migration, is that CagA (cytotoxin-associated gene A product), secreted during *H. pylori* activation of RHOA, through SHP-2 (encoded by *PTPN11*), actuates a Raf/Mek/ERK signaling cascade ([@B21]). Moreover, we found RHOA to be involved in LPA-induced transcription of the metastasis-associated urokinase-type plasminogen activator receptor (uPAR, encoded by *PLAUR*), resulting in GC cell invasion, through an unknown mechanism ([@B36]). In another study, LPA-induced RHOA activity was suppressed by cross-linked hyaluronic acid gel, in a GC cell line (AGS), thereby inhibiting GC cell migration ([@B40]). While we could find no literature regarding germline *RHOA* mutations, a somatic mutation, RHOA-G17V, has been reported to positively associate with peripheral T-cell lymphoma chemoresponse ([@B46]).

Activating invasion by RHOA in GC is also mediated by CXCL12, a ligand for CXCR4, leading to activation of RHOA, Rac, and Cdc42 through mTOR signaling ([@B7]). In fact, rapamycin, an inhibitor of mTOR signaling, suppressed GC cell migration induced by CXCL12, indicating mTOR signaling as a possible therapeutic target in GC ([@B7]). Moreover, GC cell motility was induced by the C5a receptor (CD88), in association with activated RHOA ([@B31]), while more recently, RHOA's role, in activating invasion, was revealed to be epigenetically regulated by the non-coding RNA, miR-31, potentially targeting *RHOA*, in MKN-45 GC cells ([@B39]).

Growth factors can also induce GC cell invasion and migration. For example, TGFβ1 signaling activated RHOA, leading to scirrhous GC cell migration, via the epithelial-to-mesenchymal transition (EMT) ([@B61]). More specifically, in scirrhous GC cell lines, RHOA activity was successfully repressed by an antagonist of the TGFβ receptor type I (encoded by *TGFBR1*), a mediator of TGFβ1 signaling ([@B61]). Additionally, RHOA activity was reported as promoted by the maternal embryonic leucine zipper kinase (gene symbol, *MELK*), in GC cell migration ([@B12]).

Dietary constituents can also regulate GC cell migration and invasion, through RHOA suppression ([@B26]). For example, benzyl isothiocyanate (BITC), an isothiocyanate found in mustards, repressed both *RHOA* and *FAK* mRNAs, inhibiting migration of AGS GC cells ([@B26]). RHOA also closely aligned with ROCK, which regulated invasion of OCUM-2MD3, a scirrhous GC cell line ([@B47]).

Another dietary constituent, of watercress, phenethyl isothiocyanate (PEITC), downregulated AGS GC cell migration, through RHOA activity inhibition, leading to suppression of the metastasis-promoting urokinase-type plasminogen activator (UPA), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and NF-κB ([@B70]). A constituent of numerous plants, gallic acid, also suppressed RHOA activity, and that of the GTPases Cdc42, and Rac1, leading to inhibition of AGS GC cell migration ([@B27]). The flavonoid nobiletin, isolated from citrus fruit peels, was similarly reported to inhibit FAK/Ras enzymatic activity, downregulating RHOA/Cdc42/Rac1 protein expression, to subsequently inhibit AGS GC cell migration ([@B41]). We note that the study of dietary agents associated with reduced cancer risk, by identifying their potentially antineoplastic constituents in treatment of cultured cancer cells, is an essential first preclinical step ([@B69]). However, this must be then translated to animals, disease models, etc., prior to any remote possibility of use in humans ([@B9]).

Epigenetically, GC cell invasion was suppressed by the non-coding RNA, miR-647, through a RHOA-mediated SRF/MYH9 axis ([@B71]), while miR-29, in association with chemotherapy, inhibited GC cell invasion and migration, *in vitro* and *in vivo* ([@B66]).

The cancer hallmark term, "resistance to cell death" (\#2 above), also highly associated with RHOA. While a role for RHOA in apoptosis remains unresolved in GC ([@B3]), evidence does exist for apoptotic effects of RHOA/Rock signal pathway inhibition, in GC ([@B3]; [@B68]). One recent report showed that RHOA activation, in association with cell detachment-induced apoptosis (i.e., anoikis, cell death due to loss of cell-extracellular matrix contacts), resulted in enhanced assembly of actin filaments and focal adhesions ([@B3]). Also, resistance to chemotherapy-induced apoptosis ([@B33]), in GC cells, was reported to be mediated by RHOA activation ([@B32]). Activation of RHOA and NF-κB, by *H. pylori* infection, induced plasminogen activator inhibitor-2 (PAI-2; SERPINB2), leading to inhibition of apoptosis in gastric epithelial cells ([@B65]).

The cancer hallmark term, "sustainment of proliferative signaling" (hallmark \#3 above), has yet to be clearly linked to GC, with specific regard to RHOA ([@B17]). However, a few studies have implicated RHOA as playing roles in GC cell proliferation. For example, one study showed that RHOA inhibition suppressed GC cell growth, albeit with lack of a proposed molecular mechanism ([@B45]). Also, when RHOA was inhibited in the GC cells, via siRNA, G1/S progression was slowed, through upregulation of the INK4 family cell cycle inhibitors, p15^INK4b^ (*CDKN2B*), p16^INK4a^ (*CDKN2A*), p18^INK4c^ (*CDKN2C*), and p19^INK4d^ (*CDKN2B*). These events were postulated as mediated by RHOA/Rock pathway inhibition ([@B74]), and resulted in inhibition of CDK4 and CDK6 activity. Also, p21^CIP1^ (*CDKN1A*) and p27^KIP1^ (*CDKN1B*), cell cycle inhibitors of CDK2, were upregulated through a RHOA/mDia pathway, during RHOA suppression ([@B74]). However, the detailed mechanisms of this phenomenon remain unknown.

The tumor microenvironment (e.g., stromal cells, cancer-associated fibroblasts, etc.) also plays an important role in multiple cancer hallmarks ([@B22]). In tumor microenvironment, tumor stroma interacting with cancer cells support tumor growth and progression, and include heterogeneous cell types (fibroblasts, myofibroblasts, endothelial cells, macrophages, diverse immune cells, and extracellular matrix (ECM)) ([@B63]). Spheroids can mimic these multicellular nature and ECM, while monolayer system is too simplified to represent the interaction of a growing tumor and stroma ([@B63]). Moreover, it is believed that distinct regions of the microenvironment comprise a cancer stem cell (CSC) "niche" ([@B56]). Also, tumor-derived spheroids are used to purpose for the enrichment of CSCs or stem-like cells ([@B29]). In one CSC assay, spheroid formation ([@B77]), RHOA was hyperactivated in spheroid GC cells, compared to monolayer GC cell colonies of diffuse type GC cells ([@B72]). Another stemness phenotype, drug expulsion by the membrane transporter P-glycoprotein, was also found to be attenuated by RHOA pharmacological inhibition ([@B55]). These findings may implicate RHOA signaling in the promotion of CSC phenotypes ([@B72]).

Aberrant post-transcriptional events may also contribute to regulation of RHOA signaling. For example, recently, a contradictory role for RHOA, in two Lauren diffuse type GC cell lines (HSC-59, GSU) of 17 GC cell lines (12 for diffuse type and five for intestinal type), was suggested, in that low RHOA protein expression, due to aberrant alternative splicing of *RHOA* transcripts, was found in the two GC cell lines (HSC-59, GSU) ([@B48]).

GC cell lines ranges in diverse histology, Lauren classification, *RHOA* mutation statuses, and RHOA protein expression ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). Thus, different GC cell line characteristics may impact on RHOA function, and GC cell line studies above need to be carefully interpreted.

The molecular mechanisms in this section are summarized in [Figure 2](#F2){ref-type="fig"}. Overall, the majority of RHOA functions, in invasion, primarily encompass cancer hallmark \#2 (resistance to cell death). Other hallmarks should be investigated in future.

![A diagram of molecular networks of RHOA in GC. In GC, regulation of RHOA described in this review was represented in the networks. Solid lines represents established regulations, and dashed lines the regulations described in this review for GC.](fgene-10-00438-g002){#F2}

Biomarker and Clinical Relevance of RHOA, and Its Molecular Regulators
----------------------------------------------------------------------

*RHOA* mRNA and its protein expression have demonstrated clinical relevance, including overall survival and GC tumor stage, and in this section, we searched for RHOA clinicopathological associations out of the 63 publications in the previous section. This search revealed 10 reports ([@B45]; [@B54]; [@B28]; [@B8]; [@B72], [@B73]; [@B16]; [@B38],[@B39]; [@B62]) of assessment of RHOA immunohistochemical (IHC) staining and its mRNA expression ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). In addition, manually collected studies were reviewed in this section.

For example, [@B28] reported that the Lauren classification, diffuse subtype, significantly associated with RHOA and specific clinicopathological characteristics, while the GC Lauren classification, intestinal subtype, did not. Moreover, IHC staining of diffuse subtype GC tumors, for RHOA, associated with advanced pathological N (nodal ingress) stages and poor prognosis (i.e., disease-free and overall survival), after surgery ([@B28]; [@B72]). In another small sample size study ([@B73]), advanced T and TMN stages showed higher *RHOA* mRNA and its protein expression, compared to early T and TMN stages. However, these results were inconsistent with those of [@B39], who reported no statistically significant difference between RHOA IHC staining and TNM stage. The inconsistency may come from clinicopathological characteristics differences (including ethnicity) and different IHC grading schemes.

[@B45] profiled RHOA IHC staining across the sequence of GC tumor development, i.e., normal mucosa, intestinal metaplasia, dysplasia, and invasion ([@B45]). Those results showed significantly higher RHOA expression in full-fledged tumors, compared to normal mucosa, intestinal metaplasia, and dysplasia, indicating progressively increasing RHOA expression during GC development. In another study, RHOA protein expression, in a small cohort (*n* = 53), showed positive association with poor GC differentiation ([@B54]). That study also confirmed statistically significant upregulation of *RHOA* mRNA expression, in malignant GC tissues, compared to adjacent normal ([@B54]). These studies correlating poor GC differentiation status with upregulated RHOA, as determined by IHC, are consistent with two other studies ([@B38],[@B39]) reporting RHOA expression to be higher in Lauren classification subtype diffuse tumors, compared to the Lauren classification intestinal subtype, with the former also positively associating with vascular invasion.

*RHOA* is also a target of miR-31, which interestingly, showed significant clinical relevance to GC ([@B8]). In that regard, RHOA IHC staining was significantly higher in tumor tissues than in adjacent normal tissues, in negative correlation with miR-31 expression ([@B8]). Another recent study ([@B16]) showed possible clinical relevance of miR-31, in that its low expression associated with advanced pathologic N stages, and positive lymphatic vessel invasion status ([@B16]). That work also indicated that such a miR-31/RHOA axis could represent a clinical marker, and possible therapeutic target, in GC.

Our recent GC study ([@B5]) also revealed that gene expression of *RHOA* was higher in stage I GC tissue samples than in adjacent normal tissues, revealing a clinical association with early stage GC. This finding was further confirmed in an independent RHOA IHC study showing that early GC (stages T1a and T1b) tissues exhibited higher RHOA protein expression, in comparison to adjacent tissues ([@B62]).

RHOA also associated with signaling by the stemness-related pathway WNT ([@B5]), as determined by a network generation algorithm, PATHOME ([@B51]), with both pathways sharing downstream genes/proteins (i.e., "crosstalking"). It has also been shown that the Wnt pathway β-catenin degenerative complex, when inhibited by Dishevelled, allows Rho/Rac to facilitate β-catenin translocation to the nucleus ([@B58]). Analogously, Wnt5a ([@B44]; [@B34]) and Wnt3a ([@B34]) were positively correlated with RHOA activation, in association with GSK3-β phosphorylation. In the brain, RHOA inhibition enhanced GSK3-induced phosphorylation and degradation of β-catenin, while also inhibiting membrane efflux by P-glycoprotein, a "stemness" phenotype ([@B55]). Another recent finding showed GC clinical relevance of WNT signaling (WNT5A), in terms of lymph node metastasis, Lauren classification subtype diffuse, and advanced UICC stage ([@B52]). However, clinical application of RHOA and WNT signaling ([@B51], [@B52]; [@B5]; [@B35]) yet requires functional validation, prior to assessment of therapeutic feasibility.

Currently, next-generation sequencing (NGS) data for GC patients is available in the Cancer Genome Atlas (TCGA) ([@B4]). We inspected *RHOA* mutations, copy number variations, and gene expression the TCGA stomach cancer dataset (258 patients) ([@B4]) by using cBio Portal ([@B15]). In [Supplementary Figure S3](#SM1){ref-type="supplementary-material"}, we also displayed CpG island methylator phenotype (CIMP) categories, Epstein--Barr virus (EBV) presence, microsatellite instable (MSI) status and Lauren classification along with *RHOA* genetic alterations. Somatic mutation frequency was 5.4% (14/258), and copy number alteration (CNA) frequency was 2.3% (6/258). Two out of the 14 patients having *RHOA* mutations were EBV-present. The 6 patients having CNAs were deep deletion and EBV present. Also, five out of the 6 CNA patients belonged to Lauren classification intestinal type. The TCGA created the four molecular subtypes: EBV-positive tumors, MSI tumors, genomically stable (GS) tumors, and tumors with chromosomal instability (CIN) ([@B4]; [@B75]). According to the TCGA, genetic events of *RHOA* and Rho-family GTPase-activating proteins (GAP) were the molecular subtype GS.

RHOA Therapeutic Implications in Gastric Cancer
===============================================

GC Therapeutics and RHOA
------------------------

To date, FDA-approved drugs directly targeting RHOA remain unapproved, according to the CIViC database ([@B19])^[1](#fn01){ref-type="fn"}^. However, GC RHOA signaling associated with clinical efficacy of various chemotherapeutics ([@B32]; [@B78]; [@B66]; [@B72]; [@B39]) ([Table 1](#T1){ref-type="table"}). Roles for RHOA in chemotherapeutic efficacy were also shown in Lauren diffuse GC cells ([@B72]; [@B39]). Also, in Lauren intestinal GC cell lines (AGS, SNU-638), RHOA hyperactivity reduced chemosensitivity ([@B32]; [@B78]).

###### 

RHOA involvement in actions of specific chemotherapeutics, and their descriptions.

  Compounds                                                                                              Description
  ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cisplatin ([@B66]), docetaxel ([@B66]), 5-fluorouracil ([@B39]), vincristine ([@B32]), taxol([@B32])   Non-coding RNA (miR-29, and -31) epigenetics, involved in chemotherapy efficacy, through RHOA signaling
  5-fluorouracil, cisplatin ([@B72])                                                                     CD44(+) GC CSC cell numbers were decreased by cisplatin combined with RHOA signaling inhibitors; A cancer hallmark term, resisting cell death (cancer stem-like cells, CSCs) associated.

Regarding RHOA, therapeutic agents, and their description are summarized in the table

.

RHOA signaling also associated with cisplatin and docetaxel therapeutic actions in GC, in addition to association with miR-29, a regulator of both catenin-δ (CTNND1) and RHOA, implicating non-coding RNA epigenetic effects of chemotherapeutic agents ([@B66]). Moreover, upregulation of miR-31 (a proposed regulator of RHOA ([@B49]), described above), enhanced chemosensitivity to 5-fluorouracil, in diffuse type GC MKN-45 cells ([@B39]).

Another study revealed that CD44^+^ CSCs associated with GC recurrence, following chemotherapy with 5-fluorouracil and cisplatin, in Lauren diffuse GC cells ([@B72]). Further, combination of a potential RHOA signaling inhibitor, fasudil, with cisplatin, effectively suppressed numbers of CD44^+^ CSCs, in GC ([@B72]). Although there is no postulated mechanism for CD44 association with RHOA activation, the Hippo-YAP signal pathway seems likely to link CD44 and RHOA, in other cell types ([@B76]).

Regarding targeted therapies, the U.S. Food and Drug Administration (FDA) approved the HER2 antibody trastuzumab, combined with chemotherapy, for HER2^+^ GC patients ([@B1]). However, in diffuse type GC, HER2^+^ patients represent only 2--7% of the total, underscoring the crucial need for more subtype-specific therapeutics ([@B64]). Moreover, considering the clinical importance of RHOA in diffuse (and other) type GC ([@B51]; [@B5]; [@B72]; [@B39]; [@B52]), therapeutic development strategies remain largely undeveloped ([@B64]). Also recently, ramucirumab, a targeted therapy for metastatic GC, was approved by the FDA, although it is unclear whether it impacts RHOA signaling.

Small Molecule Inhibitors for Targeting RHOA Proteins in GC
-----------------------------------------------------------

One small molecule inhibitor, Rhosin ([@B60]), inhibits RHOA signaling by directly targeting the RHOA protein, in breast and hepatocellular cancer cells ([@B60]; [@B43]; [@B53]), as well as GC cells ([@B72]). In our recent study, we demonstrated a hydrazide derivative, JK-122, as a new small molecule inhibitor that binds the RHOA active site, as determined using surface plasmon resonance, and was also antimitogenic toward GC cell lines ([@B5]).

Several chemical inhibitors of RHOA signaling do not directly target the RHOA protein, but affect RHOA signaling-related proteins ([@B43]; [@B53]). For example, CCG-1423 ([@B14]) is a small molecule that suppresses RHOA signaling ([@B14]) by binding to the phosphatase and actin regulator RPEL, to inhibit RHOA/MKL/SRF signaling ([@B24]). While unsuitable for translational development, these compounds provide proof-of-concept for experimental investigation of RHOA (and its other family members') signal inhibition ([@B53]), as the identification of therapeutic small molecule inhibitors, that selectively bind RHOA, remain urgently needed.

Conclusion
==========

Here, we reviewed literature of how RHOA's roles, in gastric cancer (GC), associate with the second-generation cancer hallmark term, "activation of invasion and metastasis" ([@B36]; [@B7]; [@B12]). Two other cancer hallmarks ("resistance to cell death" and "sustainment of proliferative signaling") also were linked to studies of GC. Cancer stem-like cells, well known inhabitants of the tumor microenvironment, have been also implicated in GC ([@B72]). Thus, molecular and biochemical studies of RHOA, as related to other cancer hallmarks, need to be performed in the future.

RHOA expression in GC, as reviewed in the literature, shows clinical association with Lauren diffuse subtype GC, and may have potential prognostic value ([@B51], [@B52]; [@B5]; [@B72]; [@B39]). However, in terms of GC therapeutic options, small chemical inhibitors that directly bind RHOA, have yet to translated to GC patients. However, our recent study ([@B5]) showed that RHOA activity could be regulated by specific small chemicals that bind the protein, indicating RHOA to be a druggable target in GC. For facilitating therapeutic discovery in GC, GC *in vitro* models should be continuously developed ([@B6]). In summary, although existing evidence demonstrates the feasibility of employment of RHOA as both a biomarker candidate and druggable target, further investigation of its application to GC (and other cancer) therapy, is urgently needed.
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